ATE431359T1 - Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie - Google Patents

Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie

Info

Publication number
ATE431359T1
ATE431359T1 AT99949923T AT99949923T ATE431359T1 AT E431359 T1 ATE431359 T1 AT E431359T1 AT 99949923 T AT99949923 T AT 99949923T AT 99949923 T AT99949923 T AT 99949923T AT E431359 T1 ATE431359 T1 AT E431359T1
Authority
AT
Austria
Prior art keywords
molecular weight
weight markers
therapy
copolymers
copolymer
Prior art date
Application number
AT99949923T
Other languages
English (en)
Inventor
Alexander Gad
Dora Lis
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22285926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE431359(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE431359T1 publication Critical patent/ATE431359T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
AT99949923T 1998-09-25 1999-09-24 Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie ATE431359T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10169398P 1998-09-25 1998-09-25
PCT/US1999/022402 WO2000018794A1 (en) 1998-09-25 1999-09-24 Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use

Publications (1)

Publication Number Publication Date
ATE431359T1 true ATE431359T1 (de) 2009-05-15

Family

ID=22285926

Family Applications (2)

Application Number Title Priority Date Filing Date
AT09004306T ATE516297T1 (de) 1998-09-25 1999-09-24 Mit copolymer 1 verwandte polypeptide zur verwendung als molekulargewichtsmarker und zur therapeutischen verwendung
AT99949923T ATE431359T1 (de) 1998-09-25 1999-09-24 Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT09004306T ATE516297T1 (de) 1998-09-25 1999-09-24 Mit copolymer 1 verwandte polypeptide zur verwendung als molekulargewichtsmarker und zur therapeutischen verwendung

Country Status (18)

Country Link
EP (3) EP1115743B1 (de)
JP (2) JP4629229B2 (de)
AT (2) ATE516297T1 (de)
AU (1) AU757413B2 (de)
CA (2) CA2343929C (de)
CY (3) CY1110490T1 (de)
DE (2) DE69940888D1 (de)
DK (3) DK2090583T3 (de)
ES (3) ES2327301T3 (de)
HK (3) HK1040521A1 (de)
HU (3) HU229289B1 (de)
IL (4) IL142116A0 (de)
NO (2) NO329877B1 (de)
NZ (1) NZ511020A (de)
PT (3) PT2239269E (de)
SI (1) SI1115743T1 (de)
WO (1) WO2000018794A1 (de)
ZA (1) ZA200102269B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
EP1098902A4 (de) 1998-07-23 2002-07-24 Yeda Res & Dev Behandlung von autoimmunkrankheiten mittels copolymer 1 und ähnlichen copolymeren und peptiden
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
ZA200206457B (en) 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2001097785A2 (en) * 2000-06-20 2001-12-27 Caprion Pharmaceuticals Inc. Basic copolymers for the treatment of prion-related-disease
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
DE02800437T1 (de) * 2001-10-03 2004-11-11 The President And Fellows Of Harvard College, Cambridge Copolymere zur unterdrückung von autoimmunkrankheiten und anwendungsverfahren
NZ533327A (en) 2001-12-04 2006-11-30 Teva Pharma Processes for the measurement of the potency of glatiramer acetate
WO2004064717A2 (en) 2003-01-21 2004-08-05 Yeda Research And Development Co. Ltd. Cop 1 for treatment of inflammatory bowel diseases
DK1651161T3 (da) 2003-08-07 2012-01-30 Healor Ltd Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
NZ549731A (en) * 2004-03-01 2009-11-27 Peptimmune Inc Methods and compositions for treatment of autoimmune diseases
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
HUE028833T2 (en) 2004-09-09 2017-01-30 Yeda Res & Dev Polypeptide mixtures, compositions containing them, process for their preparation, and applications
US7858337B2 (en) 2007-03-08 2010-12-28 Novartis Ag Process for the manufacture of a composite material
DE202010018377U1 (de) 2009-08-20 2016-02-25 Yeda Research And Development Co., Ltd. Niedrigfrequente therapie mit glatirameracetat
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
KR20140019296A (ko) 2010-10-11 2014-02-14 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트에 대한 임상 반응의 예측성 바이오마커로서의 사이토카인 바이오마커
WO2012123959A2 (en) 2011-02-14 2012-09-20 Usv Limited Copolymer-1, process for preparation and analytical methods thereof
EP2765857A4 (de) 2011-10-10 2015-12-09 Teva Pharma Einzelnukleotidpolymorphismen zur vorhersage des klinischen ansprechens auf glatirameracetat
US9617596B2 (en) 2012-10-10 2017-04-11 Teva Pharmaceutical Industries, Ltd. Biomarkers predictive for clinical response for glatiramer acetate
CN104098655B (zh) * 2013-04-09 2018-01-30 深圳翰宇药业股份有限公司 用于合成醋酸格拉替雷的质谱内标的多肽
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105218646B (zh) * 2014-06-24 2018-09-21 深圳翰宇药业股份有限公司 一种用于检测醋酸格拉替雷样本的uplc方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN112649537B (zh) * 2015-04-28 2024-03-29 深圳翰宇药业股份有限公司 多肽混合物高效液相色谱分析方法
EP3147667B1 (de) * 2015-09-24 2019-06-12 CHEMI S.p.A. Analyse der molekulargewichtsverteilung von komplexen polypeptidmischungen
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2009996A1 (en) * 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers

Also Published As

Publication number Publication date
EP2090583A1 (de) 2009-08-19
ES2327301T3 (es) 2009-10-27
JP2002525378A (ja) 2002-08-13
HU229720B1 (en) 2014-05-28
IL209190A (en) 2017-11-30
CA2794705C (en) 2017-07-18
SI1115743T1 (sl) 2010-01-29
AU757413B2 (en) 2003-02-20
EP1115743A1 (de) 2001-07-18
HUP0103889A2 (hu) 2002-03-28
EP2239269B1 (de) 2013-01-16
CY1112197T1 (el) 2015-12-09
JP2010271325A (ja) 2010-12-02
CA2794705A1 (en) 2000-04-06
EP1115743A4 (de) 2005-04-27
ZA200102269B (en) 2002-03-19
PT2239269E (pt) 2013-04-09
NO20011441D0 (no) 2001-03-21
IL209189A (en) 2017-11-30
PT1115743E (pt) 2009-07-07
JP4629229B2 (ja) 2011-02-09
NO20011441L (no) 2001-05-25
HU229289B1 (en) 2013-10-28
EP2239269A1 (de) 2010-10-13
JP4903886B2 (ja) 2012-03-28
WO2000018794A1 (en) 2000-04-06
ES2369642T3 (es) 2011-12-02
HK1149279A1 (en) 2011-09-30
HU229719B1 (en) 2014-05-28
CY1113932T1 (el) 2016-07-27
NO20100442L (no) 2001-05-25
CA2343929C (en) 2013-01-29
IL209189A0 (en) 2011-01-31
DK2239269T3 (da) 2013-04-29
ES2408706T3 (es) 2013-06-21
IL142116A0 (en) 2002-03-10
DK2090583T3 (da) 2011-09-12
HK1040521A1 (en) 2002-06-14
CA2343929A1 (en) 2000-04-06
PT2090583E (pt) 2011-09-14
IL209190A0 (en) 2011-01-31
NO329877B1 (no) 2011-01-17
EP2090583B1 (de) 2011-07-13
HK1133021A1 (en) 2010-03-12
NZ511020A (en) 2003-06-30
NO336685B1 (no) 2015-10-19
IL142116A (en) 2010-12-30
ATE516297T1 (de) 2011-07-15
EP1115743B1 (de) 2009-05-13
CY1110490T1 (el) 2015-04-29
DE09004306T1 (de) 2010-12-09
DE69940888D1 (de) 2009-06-25
AU6269599A (en) 2000-04-17
DK1115743T3 (da) 2009-07-27
HUP0103889A3 (en) 2004-03-01

Similar Documents

Publication Publication Date Title
ATE431359T1 (de) Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie
DK0397633T3 (da) Fibronectinbindende protein samt fremstilling deraf
ATE529444T1 (de) Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
TR200001709T2 (tr) Yeni neisseria meningitids yüzey proteini
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
NO882380L (no) Fibfonektin-bindende protein, samt fremstilling derav.
ATE312179T1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
ATE242883T1 (de) Verfahren zur bestimmung von blutgerinnungsfaktoren viii und ix
DE69519654D1 (de) htFIIIA Gen
DE68902792D1 (de) Mittel zur kosmetischen oder pharmazeutischen verwendung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1115743

Country of ref document: EP